PLAY PODCASTS
Brazil's RDC 751 Maze: Pure Global on MedTech's Hidden Submission Traps.

Brazil's RDC 751 Maze: Pure Global on MedTech's Hidden Submission Traps.

LATAM MedTech Insights · Ran Chen

January 31, 20262m 11s

Audio is streamed directly from the publisher (episodes.captivate.fm) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.

Show Notes

This episode of LATAM MedTech Insights dives into the critical challenges emerging from Brazil's new medical device regulation, RDC 751/2022. As of last week, an increasing number of international manufacturers are facing surprising rejections from ANVISA. The issue goes far beyond simple paperwork; it reflects a fundamental misunderstanding of the heightened scrutiny now applied to clinical data, risk management, and technical documentation. We explore the hidden complexities that are tripping up even experienced regulatory affairs teams. We break down the specific areas where ANVISA is focusing its attention, from demanding localized clinical evidence to flagging minor inconsistencies in product labeling. This episode is essential for any MedTech company looking to enter or maintain its presence in the Brazilian market. **What You'll Learn:** - Why is Brazil's RDC 751 proving to be more than just a document reformatting exercise? - What is the single biggest mistake foreign manufacturers are making in their new ANVISA submissions? - How can your existing CE-marked or FDA-approved clinical data lead to a rejection in Brazil? - Are you correctly understanding the difference between device 'grouping' (agrupamento) and 'kits' (conjunto)? - What are the unwritten expectations from ANVISA reviewers when they examine your technical dossier? - How can you avoid a six-month delay by getting your Instructions for Use and labeling right the first time? - How can you transform the challenges of RDC 751 into a strategic advantage for market entry? Navigating global markets requires deep local expertise and cutting-edge tools. Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, leveraging local experts in Brazil and advanced AI to streamline market access. From initial regulatory strategy to post-market surveillance, we act as your local representative to ensure your success. To learn how we can help you conquer the Brazilian market, contact us at [email protected] or visit https://pureglobal.com/.